Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-dose, low-volume chemonucleolysis. A biochemical study.

P M Dando1, J R Jenner, A Charles

  • 1Department of Biochemistry, Strangeways Research Laboratory, Cambridge, United Kingdom.

Spine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Masses in Childhood: An Australian Perspective.

Journal of paediatrics and child health·2025
Same author

Generalized sarcoidosis associated with hypertrophic osteopathy in a Standardbred racehorse.

Journal of equine veterinary science·2024
Same author

Selection for treatment of patients at high risk of fracture by the short versus long term prediction models - data from the Belgian FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohort.

Bone reports·2023
Same author

[Physical activity in nursing homes: contributions of the SENIOR cohort].

Revue medicale de Liege·2023
Same author

Are there specific clinical risk factors for the occurrence of multiple fractures? The FRISBEE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023

Low-dose chymopapain injections effectively increase urinary glycosaminoglycans in sciatica patients. This suggests lower doses may be as effective as standard doses for chemonucleolysis, offering a potential alternative treatment.

Area of Science:

  • Biochemistry
  • Orthopedics
  • Pharmacology

Background:

  • Persistent sciatica often results from single intervertebral disc protrusion.
  • Chemonucleolysis using chymopapain is a treatment option for sciatica.
  • Glycosaminoglycans (GAGs) are key components of the intervertebral disc matrix.

Purpose of the Study:

  • To investigate the effect of different chymopapain doses on urinary glycosaminoglycan excretion.
  • To compare the efficacy of low-dose, low-volume versus standard-dose chemonucleolysis.

Main Methods:

  • Thirty patients with sciatica received either 0.5 ml (2.0 mg) or 2.0 ml (8.0 mg) of chymopapain.
  • Serial 24-hour urine samples were collected pre- and post-injection for 5 days.
  • Urinary glycosaminoglycans were analyzed to assess GAG release.

Related Experiment Videos

Main Results:

  • Both low-dose and standard-dose chymopapain significantly increased urinary GAG excretion.
  • No significant difference in total GAG excretion was observed between the two dosage groups over the 5-day period.
  • Low-dose chemonucleolysis demonstrated comparable GAG release to standard doses.

Conclusions:

  • Low-dose, low-volume chemonucleolysis may be as effective as standard doses in releasing glycosaminoglycans from intervertebral discs.
  • These findings suggest a potential for reduced dosage in chymopapain treatment for sciatica.
  • Further research could explore the clinical outcomes associated with lower chymopapain doses.